The Drug-to-Antibody Ratio (DAR) is the most important quality attribute of ADC drugs because it determines the “payload” that can be delivered to tumors, directly impacting safety and efficacy. Here, we […]
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the […]
The popularity of thiol coupling in ADC preparation can be attributed to three factors: It is essential to note that a reduction step is always required before coupling to release […]
B7-H3 and B7-H4 are type I transmembrane proteins belonging to the B7 family. Their abnormal expression is associated with many diseases such as colon cancer, breast cancer, liver cancer, and […]
Introduction to HER and ADCs Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play a core role in regulating cell proliferation, […]
In recent years, antibody-drug conjugates (ADCs) have achieved substantial success in cancer therapy. Typically, an antibody or peptide in a conjugated drug acts as a precisely located “navigator” while a small-molecule […]
Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play central roles in regulating cell proliferation, survival, differentiation, and migration. Overexpression of […]